Showing 2021-2030 of 4063 results for "".
- Alcon Adds New Gemstone Collection to Air Optix Colors Lens Portfolio and Introduces 2-Count Packshttps://modernod.com/news/alcon-adds-new-gemstone-collection-to-air-optix-colors-lens-portfolio-and-introduces-2-count-packs/2480236/Alcon has introduced its new Air Optix Colors Gemstone Collection of color contact lenses, with three new colors – Amethyst, True Sapphire, and Turquoise. Now offering a total of 12 colors, Air Optix Colors lenses appeal to a wide range of patients and offer a strong incremental revenue potential
- Alcon Presents Comprehensive Scientific Program With 59 Abstracts at ESCRS 2022https://modernod.com/news/alcon-presents-comprehensive-scientific-program-with-59-abstracts-at-escrs-2022/2481096/Alcon will present extensive data during the 2022 Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Milan, Italy, September 16-20. The official program will feature 59 abstracts, with more than 30 focused on Alcon’
- The American Optometric Association (AOA) Launches Nationwide Campaign to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-launches-nationwide-campaign-to-make-2020-the-year-of-the-eye-exam/2477227/The American Optometric Association (AOA) announced the official launch of the #2020EyeExam campaign to make eye health and vision care a national priority in 2020. The public awareness campaign underscores the importance of receiving an in-person comprehensive eye examination with an AOA doctor
- SECO International Names J. Max Ernst, OD, as 2020 Presidenthttps://modernod.com/news/seco-international-names-j-max-ernst-od-as-2020-president/2476329/SECO International, the world’s largest educational conference, has announced that J. Max Ernst, OD, will become the next SECO International President. Dr. Ernst will officially accept the honor during the House of Delegates meeting, held during SECO 2019, Saturday, February 23, from 3:15 pm-5 pm
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- Antigua and Barbuda to Host First Global Summit for Eye Health in November 2026https://modernod.com/news/antigua-and-barbuda-to-host-first-global-summit-for-eye-health-in-november-2026/2485941/Key Takeaways Antigua and Barbuda will host the first-ever Global Summit for Eye Health on November 2, 2026, bringin
- Fifteenth Annual Eyes on Capitol Hill Advocacy Eventhttps://modernod.com/news/fifteenth-annual-eyes-on-capitol-hill-advocacy-event/2477302/Prevent Blindness will be holding its 15th annual “Eyes on Capitol Hill” advocacy day on February 26, 2020, in Washington, D.C. The annual program provides those from across the United States the opportunity to meet with Congressional and Senate members, and their staff, to discuss vision issues
- Atsena Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)https://modernod.com/news/atsena-announces-alignment-with-fda-on-regulatory-pathway-to-approval-for-atsn-201-in-x-linked-retinoschisis-xlrs/2482878/Atsena Therapeutics announced that the FDA has agreed to the expansion of the company’s ongoing phase 1/2 LIGHTHOUSE study of ATSN-201 into a continuous phase 1/2/3 trial, enabling it to serve as a pivotal trial to support a Biologics License Application (BLA) submission for the t
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479335/Nicox SA announced that the last patient in the NCX 4251 Mississippi phase 2b blepharitis clinical trial has now completed the 2-week treatment phase as well as the required 2-week follow up period. Topline results are expected to be announced in September 20
- Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDAhttps://modernod.com/news/nicox-outlines-plans-to-progress-ncx-4251-into-phase-2b-trial-following-positive-meeting-with-fda/2477548/Nicox SA announced that it has held a Type C meeting with the FDA in which the data from the recently completed Danube phase 2 clinical trial of NCX 4251 was reviewed and the next NCX 4251 trial designs were discussed. Given the positive Danube phase 2 trial results in reduction of the signs and